

ANALYTICA LTD | ABN 12 006 464 866

7 November 2014

## **ASX ANNOUNCEMENT**

## NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT 2001

On 5 November 2014, Analytica Limited (**Company**) issued 9,984,332 fully paid ordinary shares in the Company (**Shares**) at \$0.03 per share to institutional and sophisticated investors (**Share Placement**).

As required under section 708A(6) of the Corporations Act 2001 (Act), the Company gives notice that:

- 1. The Shares were issued without disclosure to Eligible Shareholders under Part 6D.2 of the Act.
- 2. This notice is being given under section 708A(5)(e) of the Act.
- 3. As at the date of this notice, the Company has complied with:
  - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
  - b. section 674 of the Act.
- 4. As at the date of this notice, there is no excluded information as defined in section 708A(7) and section 708A(8) of the Act which is required to be disclosed by the Company.

**ENDS** 





ANALYTICA LTD | ABN 12 006 464 866

## About Analytica Limited

Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach<sup>™</sup> comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.

PeriCoach<sup> $\mathbb{M}$ </sup> has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. The product is not available for sale in the USA.